Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Develops new antibiotics by targeting ribosome of infectious diseases.
Year Established: | |
Funding: | 25 |
Address: | 300 George Street Suite 301 New Haven, CT, 06511-6663 USA |
Telephone: | 2036245606 |
Mobile: | |
Fax: | 203.624.5627 |
Mail: | info@rib-x.com |
Company URL: | http://www.rib-x.com |
Rib-X is dedicated to building a strong and diverse company by hiring and keeping smart, motivated and creative people. Our atmosphere of intellectual challenge and cutting edge technology provides a stimulating and motivating work environment which offers significant opportunities for our employees to grow their skills and advance their careers. Beyond this there are several distinctive features about Rib-X which make it an exciting place to work. First, we promote a culture of collaboration and teamwork. Many employees participate in cross-functional project teams that drive our products and partnerships forward or otherwise work closely with people from different functional areas. Additionally we've developed an environment in which each person is capable of making an impact on the company and is recognized for a job well done. We firmly believe that each person can and should make a difference to the company's success. Finally, an important element of our culture is our open communication and informal atmosphere. This coupled with a work ethic that is keenly focused on achieving results allows us to more rapidly get things done and still have fun while doing it.
03/23/10
Rib-X Appoints Mark Leuchtenberger as President and CEO
01/20/10
Rib-X Appoints MedImmune's Peter Greenleaf to Board
12/08/09
Rib-X Pharmaceuticals Expands License Agreement with Yale University on New Ribosome Technology
09/16/09
Rib-X Pharmaceuticals, Inc., Appoints Tony Zook of MedImmune to Board of Directors
09/14/09
Rib-X Pharmaceuticals Receives Award from NIAID to Develope Antibiotic Treament for Gonorrhea
09/10/09
Rib-X Pharmaceuticals to Present at the 49th ICAAC
09/04/09
Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
06/30/09
Rib-X Pharmaceuticals, Inc., Appoints Dr. Russell Greig to Board of Directors
04/15/09
Rib-X Granted Key Antibiotic Patent in China
01/26/09
Rib-X Pharmaceuticals Reports Positive Phase 2 Results for Delafloxacin for Complex Infections
12/08/08
Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
11/04/08
Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
10/31/08
Rib-X C.E.O. Susan Froshauer, Ph.D., Honored by The Connecticut Women's Hall of Fame
10/20/08
Rib-X Pharmaceuticals, Inc. to Present at the 2008 ICAAC/IDSA Joint Meeting
09/08/08
Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
09/02/08
Rib-X Pharmaceuticals, Inc. Appoints Dr. Joseph Amprey of MedImmune Ventures to Board of Directors
08/27/08
Rib-X Pharmaceuticals, Inc. to Present at the Thomas Weisel Partners Healthcare Conference
08/05/08
Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
05/10/08
DNA EpiCenter Announces Barbara McClintock, Ph.D., 2008 Class of DNA EpiCenter Scholars
05/06/08
Rib-X Pharmaceuticals, Inc. Appoints Nancy Motola as Senior Vice President of Regulatory Affairs
04/14/08
Rib-X Pharmaceuticals, Inc. Renews Collaborative Agreement with the Medical Research Council
04/03/08
Rib-X Pharmaceuticals, Inc. to Present at 10th Annual Superbugs & Superdrugs Conference
01/04/08
Rib-X Pharmaceuticals, Inc. Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
Warburg Pincus LLC